HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Futura Pens Deal With Cooper To Launch Erectile Dysfunction Gel In Europe

Executive Summary

Futura Medical's novel OTC topical erectile dysfunction treatment MED3000 will be launched across numerous European markets by France's Cooper Consumer Health.

You may also be interested in...



Futura Extends Europe Licensing Agreement With Cooper For Eroxon ED Gel

Futura Medical has extended its licensing agreement with Cooper Consumer Health for the rights to market its Eroxon topical, gel-based erectile dysfunction treatment throughout the European Economic Area, United Kingdom and Switzerland until 2029. 

Female Sexual Dysfunction, China, Next On The Agenda For Eroxon Creator Futura

Drug-free erectile dysfunction “stimgel” creator Futura wants to see if the technology underpinning Eroxon can be applied to female sexual dysfunction. Breaking into China is also high up on the agenda for the UK-based R&D company's CEO James Barder, he reveals in this exclusive interview.

UK Cialis Rx-To-OTC Switch World-First For Sanofi, H2 2023 Launch Planned

The UK is the first country to allow OTC access to Sanofi's tadalafil-based erectile dysfunction drug Cialis following a successful switch. Approved as a pharmacy medicine, Sanofi will launch Cialis Together in the second half of the year. Cialis will compete against Viatris' sildenafil-based Viagra Connect in the men's sexual health and wellness category, which has seen a proliferation of products in recent months.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152561

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel